A Phase 2 interventional study of Lactiplantibacillus plantarum Probiotic Mixture and Placebo comparator containing maltodextrin in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic and Overweight (BMI > 25), sponsored by AB Biotics, SA. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by AB Biotics, SA (part of Kaneka Corporation) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain — 11 open to participants now, 15 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Spain.
Among the 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain, this one is the 49th largest by planned enrollment of the 66 interventional ones that give a count, is the only one that started in 2026, is one of 32 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 76th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →11 of the 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Spain, United States, Argentina and 20 more countries
Ages 18–80
Hospital General Universitario Gregorio Marañon · Sites in Spain
Ages 50–75
The Cleveland Clinic · Sites in Spain, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in Spain, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 34 · Phase 3 17 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 206 across the 66 interventional studies, 777 across the 12 observational. Of the 52 that completed or were terminated, 32 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under AB Biotics, SA, one of the names counted as Kaneka Corporation. Under that name alone:
AB Biotics, SA is the lead sponsor of 26 studies on the registry; 4 are open to participants now.
Kaneka Corporation has 2 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07193927AB Biotics, SAInvestigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | 2027-02-01 |
| NCT07658755Hospital General Universitario Gregorio MarañonAutomated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
The main questions it aims to answer are:
Can the probiotics improve liver fat and stiffness as measured by non-invasive imaging (FibroScan® CAP and FAST scores)? Does the probiotic affect other health markers like cholesterol, blood sugar, inflammation, and gut bacteria?
Researchers will compare people taking the probiotic to those taking a placebo (a capsule with no active ingredients) to see if the probiotic has beneficial effects.
Participants will:
Be randomly assigned to take either the probiotic or placebo daily for 6 months.
Attend 3 study visits (at the start, 3 months, and 6 months). Provide blood and stool samples. Undergo liver scans (FibroScan®). Complete a health and nutrition questionnaire.
This study includes adults aged 18-65 with moderate MASLD and certain metabolic health conditions. Participants must not be pregnant, breastfeeding, or taking certain medications or supplements that could interfere with the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Having at least three of the following features compatible with metabolic syndrome:
i. Waist circumference ≥ 102 cm in males and ≥ 88 cm in females. ii. Fasting serum glucose (≥ 5.6 mmol/L or 100 mg/dl). iii. (HbA1c ≥ 5.7%/ 39 mmol/L). iv. Diagnosed or treated for type 2 diabetes. v. High blood pressure (≥ 130/85 mmHg). vi. High plasma triglycerides (≥ 1.70 mmol/L or 150 mg/dl). vii. Lower plasma of High-Density Lipoprotein (HDL cholesterol) (≤ 1.0 mmol/L or 40 mg/dl for males and ≤ 1.3 mmol/L or 50 mg/dl for females).
Exclusion Criteria:
Patients with at least one of the following concurrent conditions:
i. Type I diabetes ii. Uncontrolled type II diabetes ( >8%) iii. Hypertriglyceridemia > 350mg/dl iv. (HIV) infection v. Diagnosis of hemochromatosis
History of:
i. Cardiovascular disease (ischemic heart disease, heart failure, cerebrovascular disease, periphreal vascular disease).
ii. Cancer or . iii. Gastrointestinal surgery in the previous year (with the exception of appendicitis).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Lactiplantibacillus plantarum Probiotic Mixture
Dietary Supplement: Placebo comparator containing maltodextrin
A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.
Placebo comparator containing maltodextrin
Changes in MASLD from baseline
Evaluated by CAP (controlled attenuation parameter, dB/m) and FAST score \[determined with FibroScan®\]
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in Liver Fibrosis (kPa)
Time frame: From enrollment to the end of treatment at 6 months.
Changes form baseline in MASLD related index - FLI
Evaluated by Fatty Liver Index (FLI)
Time frame: From enrollment to the end of treatment at 6 months.
Changes form baseline in MASLD related index - FIB-4
Evaluated by Fibrosis 4 score (FIB-4)
Time frame: From enrollment to the end of treatment at 6 months.
Changes form baseline in MASLD related index - APRI
Evaluated by Aspartate aminotransferase-to-platelet ratio index (APRI)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in metabolic syndrome score (siMS)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in weight (kg)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in height (cm)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in Body Mass Index (BMI)
Body Mass Index (BMI) is a person's weight (kg) divided by the square of height (m).
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in waist circumference (cm)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in hip circumference (cm)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in waist/hip ratio
Waist/hip ratio is measured as the waist circumference (cm) divided by the hip circumference (cm).
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in systolic and diastolic blood pressure.
Time frame: From entollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of blood-based cell profile.
Blood count red cell line, white cell line, and platelet line.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum liver enzyme concentrations
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase (GGT), alkaline phosphatase (AP)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis insulin resistance-related variables
Fasting serum glucose, insulin, glycosylated haemoglobin (HbA1c)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of cholesterol and fatty acid concentrations:
Total cholesterol, low-density lipoprotein, high-density lipoprotein, cholesterol, triglycerides.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of high-sensitivity C-reactive protein (hsCRP) concentration.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of albumin concentration
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of total bilirubin (TBIL)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of kidney function biomarkers
Uric acid, creatinine (CREA), and blood urea nitrogen (BUN)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of thyroid hormones
Thyrotropin (TSH), thyroxine (T4), triiodothyronine (T3), parathyroid hormone (PTH)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of iron binding capacity
Ferritin, transferrin, binding capacity
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of electrolytes
Sodium (Na), potassium (K), chloride (Cl)
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of estimated glomerular filtration rate
Estimated glomerular filtration rate (eGFR) measurements developed by the Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration research group.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum analysis of nutritional and metabolic biomarkers
Magnesium (Mg), phosphate (P), iron (Fe), calcium (Ca), total protein, cortisol, 25-hydroxyvitamin D.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in serum metabolite profile by Elevated Global metabolome analysis (amine/phenol and acid channels CIL LC-MS profiling)
Quantification of metabolites (around 850 or more), with a minimum confidence of 90% in the identifications.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in gut microbiota diversity
Evaluated through shot gun metagenomics 10GB/spl (Sample QC + Nextera DNA XT (META) Library and NovaSeqX150PE 10 Gb/sample.
Time frame: From enrollment to the end of treatment at 6 months.
Changes from baseline in gut microbiota relative abundance
Evaluated through shot gun metagenomics 10GB/spl (Sample QC + Nextera DNA XT (META) Library and NovaSeqX150PE 10 Gb/sample.
Time frame: From enrollment to the end of treatment at 6 months.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 10 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →